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Abstract
The research examined the frequency and nature of carbohydrate metabolism disorders in patients with primary hypothy-
roidism. In 25.8% of patients increased glycemic indexes responding to a prediabetes stage were found. In patients with
thyroid hypofunction (TG) the presence of insulin resistance (IR) by defined HOMA IR and Caro indexes has been proved.
The dependence of IR severity on heaviness of hypothyroidism and BMI has been determined.
Differentiated treatment of patients with primary hypothyroidism, obesity and initial carbohydrate metabolism disorders has
demonstrated the priority of efficiency of combination therapy with appointed metformin and levothyroxine in comparison
with the basic substitution therapy. Appointment of metformin for the treatment of the patients with proven IR contributed to
the rapid compensation of hypothyroidism, normalization of carbohydrate metabolism indexes, and it is also preventing the
possible development of metabolic syndrome.
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Problem statement and analysis of the
latest research
In the contemporary medical science hypothyroidism, includ-
ing subclinical one is regarded as one of the risk factors for
cardiovascular diseases (CVD) [5, 6, 8, 9]. The prevalence of
thyroid hypothyroidism among women is 4 to 21%, among
men – 3 to 16
According to the latest researches, between hypothyroidism
and risk factors of CVD there are metabolic relationships iden-
tified and traced through obesity, arterial hypertension (AHT),
lipid and carbohydrate metabolism disorders [1, 3, 5, 11].
These factors are components of metabolic syndrome (MS),
the main mechanism of the development of which is the IR
[11].
New approaches to analyzing the IR syndrome in hypothy-
roidism are discussed. It has been established that thyroid hor-
mones regulate the synthesis and activity of protein-glucose
transporters (GLUT 1-5), affect the activity of tyrosine kinase,
which is responsible for receptor sensitivity. Hypoxic changes
in tissues in hypothyroidism stimulate process of lipid peroxi-
dation (LPO) and the formation of free radicals, which con-
tribute to the synthesis of vasoconstrictor substances, causing
activation of the immune-inflammatory system, the synthe-
sis of pro-inflammatory cytokines (tumor necrosis factor-α
(TNF-α), interleukin-6 (IL-6) that lead to the receptor defect
of immune-sensitive cells [2, 6, 8].
The analysis of effectiveness of the treatment of patients
confirms the presence of IR clinical manifestations even in
compensated hypothyroidism. Patients keep dyslipidemia,
coronary heart disease (CHD), arterial hypertension and obe-
sity. These changes do not always correlate significantly
with the level of thyroid stimulating hormone (TSH) and
tetraidothyronine (T4) [10, 11]. It has been found that pa-
tients with hypothyroidism are characterized by frequent car-
bohydrate metabolism disorders at the stage of prediabetes or
diabetes [1, 3].
In the contemporary literature, the issue of impact of
biguanides, metformin in particular as a modifier of thyrotropin-
inhibitory effect of thyroxin [7], as well as a factor of im-
proved sensitivity of the hypothalamic-pituitary-thyroid sys-
tem and peripheral tissues to thyroxin (T4) is discussed, which
leads to inhibition of processes of IR formation in this pathol-
ogy. In the scientific literature there is much evidence of posi-
tive effects of metformin not related to its anti-hyperglycemic
action [7].
Thus, the search for additional effects on pathogenic mech-
anisms of IR development at a hypothyroidism is an actual
problem of clinical endocrinology.
Objective is to improve treatment of patients with primary
hypothyroidism, obesity and initial carbohydrate metabolism
disorders by the way of drug effects on insulin resistance.
1. Materials and methods of the research
At the initial stage of the research 120 patients with uncompen-
sated primary hypothyroidism requiring replacement therapy
have been examined. Before appointment of treatment, pa-
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tients were divided into four groups, depending on the form
of hypothyroidism and BMI:
• Group 1 – patients with apparent hypothyroidism with
obesity (n = 45);
• Group 2 – patients with apparent hypothyroidism with-
out obesity (n = 40);
• Group 3 – patients with subclinical hypothyroidism
with obesity (n = 15);
• Group 4 – patients with subclinical hypothyroidism
without obesity (n = 20).
In order to compare the studied parameters with options
of norm 15 practically healthy individuals (PHI) were exam-
ined, donors selection of whom was carried out taking into
account the data history, in the absence of clinical signs of
hypothyroidism and obesity but under the normoglycemic
condition.
Inclusion criteria for patients’ participation in the study
were: a diagnosis of apparent and subclinical hypothyroidism
in combination with obesity or without excess body weight,
absence of diabetes, the patient’s consent.
An examination of the patients studied parameters of func-
tional activity of the thyroid, carbohydrate metabolism, and
IR indexes.
Capillary blood glucose level has been determined by a
glucose oxidase method on the automatic analyzer AHKM-01
(“Kverti-Med”, Ukraine). Indicators of glycosylated hemoglobin
were studied by means of ion exchange chromatography with
the help of an analyzer BIO-RAD D-10.
Determination of concentration of thyroid hormones (T3
(free), T4 (free), TSH, antibodies to thyroid peroxidase (AB to
TPO), the immune-reactive insulin level (IRI) was measured
by means of a method of enzyme-linked immunosorbent assay
on an automated analyzer Stat fax + 303 (US).
An IR state was determined by IR indexes, HOMA-IR
(Homeostasis Model Assessment Insulin Resistance) and Caro
indexes in particular. HOMA IR index was calculated by the
formula: HOMA-IR = fasting blood glucose (mmol/l) × fast-
ing insulin blood (mcU/l) / 22.5. Caro index was determined
by the formula: glucose (mmol/l) / insulin (mcU/l). Normally
HOMA IR index does not exceed 2.77; the Caro index is
higher 0.33.
Based on proven examination of IR state in patients with
hypothyroidism, and taking into account the most expressive
IR and frequent carbohydrate metabolism disorders in the
group of patients with apparent hypothyroidism and obesity,
the patients of this group participated (n = 45) at the stage of
use of the studied medicine. Examined patients were divided
into two groups:
• Group 1 – patients receiving basic therapy with levothy-
roxine (23 persons).
• Group 2 – patients receiving combination therapy with
levothyroxine and metformin (22 persons).
Average individual dose of levothyroxine was 82.6 mcg/day.
Metformin dose was 850 mg once a day.
Analysis of the received results was performed by the
way of comparing the indexes of the examination of patients
before treatment and 6 months later after the use of differential
therapy.
Statistical analysis of the results was performed by means
of the computer program Statistica-8 and a number of statis-
tical functions of the program Microsoft Excel. In order
to represent the data we used the average arithmetic mean M
and the average error of the arithmetic mean m, the number
of a variant (n), the reliability of the difference of two average
arithmetic means was determined by Student’s t-test. The
differences at p<0.05 are considered to be reliable.
To compare the reliability of the difference between the
groups of the research on the emergence of clinical symptoms
and physical changes the criterion χ2 has been used.
2. Results of the study and their
discussion
In the examined patients with hypothyroidism initial carbohy-
drate metabolism disorders such as fasting hyperglycemia and
impaired glucose tolerance (IGT) were identified. In order
to assess carbohydrate metabolism disorders we used criteria
defined by the International Diabetes Association.
Fasting Hyperglycemia (FHG) was found in 15 individuals
(12.5%) totally for all groups. In the group I – in 8 persons
(17.8%), in the group II – 6 persons (15.0%), in the group III
increased fasting blood sugar was found in 1 patient (6.7%),
and in the group IV FHG was not revealed in patients (Table
1).
Impaired glucose tolerance (IGT) was found in 16 indi-
viduals (13.3%) of all patients. In the group I – in 8 patients
(17.8%), in the group II – 5 persons (12.5%), in the group
III – in 1 patient (6.7%), in the group IV – 2 persons (10.0%)
(Table 1).
By and large, carbohydrate metabolism disorders at the
stage of prediabetes were identified in 31 individuals, rep-
resenting 25.8% of the patients, the vast majority of these
changes were found in patients with apparent hypothyroidism
(27 persons), representing 22.5% of all the patients. The
overwhelming number of cases of carbohydrate metabolism
disorders in patients of the group I proves dependence of
dysglycemia on body mass index (BMI).
In order to assess IR HOMA IR index was determined, for
calculation of which the EI blood level was examined. Sig-
nificant hyperinsulinemia was found in all groups of patients
compared to the PHI (p<0.05). In patients of the group I EI
level was 39.68±1.77 mc mU/ml, in patients of the group II –
30.90±1.24 mc mU/ml, 28.33 ±2.61 mc mU/ml in the group
III, 25.81±1.19 mc mU/ml in patients of the group IV. In PHI
EI index is detected within 12.22±0.32 mc mU/ml (p<0.05).
In patients of group I EI level was the highest and excelled
the PHI value by 3 times (p<0.05).
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Table 1. Carbohydrate metabolism disorders in patients with hypothyroidism
Index Total n=120 Group I n=45 Group II n=40 Group III n=15 Group IV n=20 p
n % n % n % n % n %
FHG 15 12.5 8 17.8 6 15.0 1 6.7 0 0.0 >0.05
IGT 16 13.3 8 17.8 5 12.5 1 6.7 2 10.0 >0.05
Note.
% - in relation to all patients in each separate group;
d - reliability index of difference in relation to the indexes of the group I.
HOMA IR index in patients with hypothyroidism of all
groups was increased in comparison with the PHI (p<0.05).
In healthy persons the mentioned index was defined within
2.52±0.05. In patients of the group I HOMA IR index was
the highest 8.70±0.41 and exceeded the PHI level almost by
3.5 times; in patients of the group II the index was 6.62±0.35,
in the group III – 5.83±0.65, and in the group IV – 5.09±0.29.
Reliability difference of HOMA IR and EI indexes was found
in groups II, III, IV in comparison with the group I (p<0.05)
(Table 2).
In the patients with hypothyroidism of all groups Caro
index was lowered by 1.5-2.0 times in comparison with the
healthy, and it was significantly different from the PHI indexes
(p<0.05). Reliability difference in Caro indexes was found
in groups II, III and IV in comparison with the group I of
patients (p<0.05) (Table 2).
Thus, when examining patients discovered increasing IR
indexes proves the existence of pathogenetic factors that affect
the state of the sensitivity of cells to insulin in hypothyroidism.
Results of comparison of the effectiveness of basic levothy-
roxine therapy for patients with hypothyroidism (group I) and
combination therapy with metformin (group II) demonstrate
positive dynamics by indexes, which were studied, in both
groups.
The provided therapy supported correction of carbohy-
drate metabolism disorders in two groups of patients. How-
ever, after 6 months normoglycemia was achieved by 37.5%
of the group I and 87.5% of the group II.
The positive dynamics was revealed in achieving thyroid
compensation in both groups. However, during this period,
the level of TSH only in patients of the group II has gained
value close to the index of PHI (p<0.05). Besides, the TSH
index in the group II after 3 months was significantly lower
than in the group where patients received basic therapy with
levothyroxine (p<0.05) (Table 3). A similar tendency was
observed in the dynamics of changes of peripheral hormones.
It has been found that treatment of hypothyroidism in pa-
tients of both groups reduces the IR, a laboratory indicator of
which is hyperinsulinemia. However, the received data show
more effective impact of combination therapy of hypothy-
roidism with metformin. So in the group I EI level decreased
by 34.7% and in the group II it decreased by 59.8%. In ad-
dition, EI levels in the group II after 6 months of treatment
significantly lowered in comparison with the group I of the
mentioned period (p<0.05) (Table 3).
The indicators of IR indexes are such as: HOMA IR and
Caro after the provided therapy by two schemes show IR
decrease in patients with thyroid hypofunction. However,
only patients of the group II reached value of IR markers
close to the PHI. HOMA IR and Caro indexes in patients of
the group II with combination therapy of hypothyroidism with
metformin were significantly different from the indexes of the
group I (p<0.05) (Table 3).
When analyzing the correlation between TSH levels and
IR indexes, it has been mentioned that even reaching compen-
sation of hypothyroidism IR manifestations remain; HOMA
IR and Caro indexes in both groups after treatment did not
achieve the PHI value. But in the group II of patients IR
indexes have changed more effectively than in the group I
of patients (p<0.05). This indicates parallel, independent of
compensation of hypothyroidism IR mechanisms, affecting
which we prevent the development of metabolic syndrome
components in the future.
3. Conclusions
1. Determination of carbohydrate metabolism indexes,
HOMA IR and Caro indexes provides early diagnosis
of IR state in patients with hypothyroidism.
2. The use of metformin in the combination therapy for
patients with primary hypothyroidism and obesity and
initial carbohydrate metabolism disorders has positive
effect on the IR indexes, promotes the normalization of
carbohydrate metabolism.
3. Appointment of metformin for the mentioned category
of patients results in thyroid compensation for a shorter
period of time in comparison with basic therapy.
4. The predominant pharmacological and therapeutic ef-
fects of the combination therapy on IR indexes and
normalization of metabolic disorders could be the basis
for appointment of metformin for patients with hypothy-
roidism, obesity and initial carbohydrate metabolism
disorders.
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Table 2. IR indexes in patients with primary hypothyroidism, (M±m)
Index PHI Group I Group II Group III Group IV
n=15 n=45 n=40 n=15 n=20
EI, mc mU/ml 12.22±0.32 39.68±1.77 * 30.90±1.24 */# 28.33±2.61 */# 25.81±1.19 */#
HOMA IR index 2.52±0.05 8.70±0.41 * 6.62±0.35 */# 5.83±0.65 */# 5.09±0.29 */#
Caro index 0.39±0.02 0.14±0.01 * 0.16±0.01 */# 0.19±0.02 */# 0.18±0.01 */#
Note.
* - difference is reliable in relation to the PHI indexes (p<0.05);
# - the difference is reliable in relation to indexes of patients in group I (p<0.05).
Table 3. The dynamics of indexes of thyroid compensation and IR in patients with hypothyroidism on the background of
combination therapy, (M±m)
Index Periods of treatment PHI Group I Group IIn = 23 n = 22
TSH, mc mU/ml
before 2.08±0.16 16.58±1.04 * 16.77±1.02 *
in 3 months 8.34±0.53 */** 6.68±0.41 */**#
in 6 months 5.28±0.36 */** 2.53±0.15**/#
EI, mc mU/ml before 12.22±0.32 39.39±2.71* 39.96±2.29*In 6 months 25.74±1.91*/** 16.46±0.72*/**/#
HOMA IR index before 2.52±0.05 8.76±0.56* 8.78±0.52*in 6 months 5.52±0.41*/** 3.50±0.16*/**/#
Caro index before 0.39±0.02 0.14±0.01* 0.13±0.01*In 6 months 0.20±0.02*/** 0.0±0.02*/**/#
Note.
* - difference is reliable in relation to the PHI indexes (p<0.05);
# - the difference is reliable in relation to indexes of patients in group I (p<0.05).
4. Prospects for further research
Prospects for further researches should be directed at studying
the long-term effects of IR correction in patients with hypothy-
roidism, obesity and initial carbohydrate metabolism disorders
with determination of the accurate dosage and continuance of
metformin therapy.
References
[1] Kihtyak OP, Skrypnyk NV, Pasyechko NV. Changes of
carbohydrate and lipid metabolism in patients with hy-
pothyroidism syndrome. Bull Sci Res. 2012;2:27–8
[2] Mitchenko OI, Logvynenko AO, Romanov VY. Optimiza-
tion of treatment dyslipidemia and disorders of carbohy-
drate metabolism in patients with arterial hypertension
with metabolic syndrome and thyroid dysfunction. Ukr J
Cardiol. 2010;1:73–80
[3] Mosqua HA, Lapovets LE, Kihtyak OP. Features cor-
relations of insulin resistance, carbohydrate and lipid
metabolism in patients with hypothyroidism. Bull Probl
Biol Med. 2013;3:212–6
[4] Pankiv VI. Syndrome hypothyroidism. Pract Thyroidol.
2011;3:224
[5] Mitchenko OI, Logvynenko AO, Romanov VY. Cardio-
vascular risk against the background of thyroid dysfunc-
tion. Heal Ukr. 2012;20(297):27–9
[6] Skrypnyk NV. Method diagnostic of hypothyroidism-
induced metabolic syndrome. Bucovina Med Bull.
2009;3:83–8
[7] Sokolova LK. Metformin. Today and future of famous
drug. J Endocrinol. 2012;17(1):89–93
[8] Tronko MD, Myshunina TN, Kalinichenko OV. Mech-
anisms of apoptosis thyroid conditions at its pathology.
Physiol J. 2009;55(6):90–102
[9] Biondi V. Cardiovascular risk in subclinical hypothy-
roidism. In: Materials I Forum of endocrinology Treat-
ment of subclinical hypothyroidism in children, women
and adults; 10-12 May 2013; Baveno-Stresa; p. 73–75
[10] Brenta G. Why can insulin resistance be a natural
consequence of thyroid dysfunction? J Thyroid Res.
Effect of Metformin on Parameters of Insulin Resistance in Patients with Primary Hypothyroidism — 5/4
2011;152:850 DOI: http://doi.org/10.4061/
2011/152850
[11] Lozanov V, Argirova R, Lozanov L. Hypothyroidism,
central obesity and metabolic syndrome correlations be-
tween thyroid stimulathing hormone, adipocitokines and
indiced of insulin resistens. Eur Thyroid J. 2014;3:122
Received: 18 February 2017
Revised: 24 March 2017
Accepted: 27 March 2017
